We continuously develop and expand our robust pipeline to address patients' unmet medical needs. Our pursuit of new medicines is fueled by the scientific curiosity of our employees, a willingness to examine new ideas, and the pairing of existing information with novel concepts.

Please note that the medicines in the pipeline below are currently under clinical trial investigation and are not yet approved.

Pipeline Chart

* As of July 2021

Pipeline Chart

3 ADCs

  • Trastuzumab deruxtecan (T-DXd, DS-8201)
  • Patritumab deruxtecan (HER3-DXd, U3-1402)
  • Datopotamab deruxtecan (Dato-DXd, DS-1062)

BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, TNBC: triple negative breast cancer

  • : Project in oncology that is planned to be submitted for approval based on the results of phase 2 trials
  • : Orphan drug designation (JP/US/EU)

Phase 1

  • (JP/US)
    NSCLC, TNBC, HR+ BC
    TROPION-PanTumor01
  • (JP/US/EU/Asia)
    NSCLC (without actionable mutation, pembrolizumab combo)
    TROPION-Lung02
  • (JP/US/EU/Asia)
    NSCLC (without actionable mutation, durvalumab combo)
    TROPION-Lung04
  • (US/EU/Asia)
    TNBC (durvalumab combo)
    BEGONIA
  • (JP/US/EU/Asia)
    NSCLC
  • (JP/US)
    EGFR mutated NSCLC (osimertinib combo)
  • (JP/US)
    BC
  • (US/EU/Asia)
    HER2+ BC 2L~/1L
    DESTINY-Breast07
  • (US/EU/Asia)
    HER2 low BC chemo naive/post chemo
    DESTINY-Breast08
  • (US/EU/Asia)
    HER2+ GC combo 2L~/1L
    DESTINY-Gastric03
  • (EU/Asia)
    HER2+ NSCLC (durvalumab combo) 1L
    DESTINY-Lung03
  • (US/EU)
    BC, bladder (nivolumab combo)
  • (US/EU)
    BC, NSCLC (pembrolizumab combo)

Phase 2

  • (US/EU/Asia)
    TNBC (durvalumab combo)
    BEGONIA
  • (US/EU)
    HER2+ GC 2L
    DESTINY-Gastric02
  • (JP/US/EU)
    HER2+/mutated NSCLC 2L∼
    DESTINY-Lung01
  • (JP/US/EU)
    HER2/mutated NSCLC 2L∼
    DESTINY-Lung02
  • (US/EU/Asia)
    NSCLC (durvalumab combo) 2L∼
    HUDSON
  • (JP/US/EU)
    HER2+ CRC 3L
    DESTINY-CRC01
  • (JP/US/EU/Asia)
    HER2+ CRC 3L
    DESTINY-CRC02
  • (US/EU/Asia)
    HER2 mutated tumor
    DESTINY-PanTumor01
  • (US/EU/Asia)
    HER2 expressing tumor
    DESTINY-PanTumor02
  • (JP/US/EU/Asia)
    NSCLC (with actionable mutation)
    TROPION-Lung05
  • (JP/US/EU/Asia)
    EGFR mutated NSCLC
    HERTHENA-Lung01
  • (JP/US/EU)
    CRC 3L

Phase 3

  • (JP/US/EU/Asia)
    HER2+ BC 3L
    DESTINY-Breast02
  • (JP/US/EU/Asia)
    HER2+ BC 2L
    DESTINY-Breast03
  • (JP/US/EU/Asia)
    HER2 low BC post chemo
    DESTINY-Breast04
  • (JP/US/EU/Asia)
    HER2+ BC post neoadjuvant
    DESTINY-Breast05
  • (JP/US/EU/Asia)
    HER2 low BC chemo naive
    DESTINY-Breast06
  • (US)
    HER2+ BC 1L
    DESTINY-Breast09
  • (JP/EU/Asia)
    HER2+ GC 2L
    DESTINY-Gastric04
  • (JP/US/EU/Asia)
    NSCLC (without actionable mutation)
    TROPION-Lung01

Alpha

  • Oncology
  • Specialty Medicines
  • Vaccine

AF: atrial fibrillation, ALL: acute lymphocytic leukemia, AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, DMD: Duchenne muscular dystrophy, GIST: gastrointestinal stromal tumor, IIS: investigator-initiated study, NSCLC: non-small cell lung cancer, PTCL: peripheral T-cell lymphoma

  • : Project in oncology that is planned to be submitted for approval based on the results of phase 2 trials
  • : SAKIGAKE Designation (JP)
  • : Orphan drug designation (JP/US/EU)

Phase 1

  • DS-7300 (JP/US)
    B7-H3-directed ADC
    Solid tumors
  • DS-6157 (JP/US)
    GPR20-directed ADC
    GIST
  • DS-6000 (US)
    CDH6-directed ADC
    Renal cell calcinoma, ovarian cancer
  • DS-1055 (JP/US)
    Anti-GARP antibody
    Solid tumors
  • DS-1211 (US)
    TNAP inhibitor
    Pseudoxanthoma elasticum
  • DS-6016 (JP)
    Anti-ALK2 antibody
    Fibrodysplasia Ossificans Progressiva
  • DS-3201 (JP/US)
    EZH1/2 inhibitor
    Non-Hodgkin‘s Lymphomas
  • PLX2853 (US)
    BET inhibitor
    AML
  • PLX2853 (US)
    BET inhibitor
    Solid tumor
  • PLX2853 (US)
    BET inhibitor
    Gynecologic neoplasms, ovarian cancer
  • PLX2853 (US)
    BET inhibitor
    Prostate cancer
  • DS-1594 (US)
    Menin-MLL binding inhibitor
    AML, ALL
  • DS-5670 (JP)
    mRNA vaccine
    COVID-19
  • VN-0200 (JP)
    RS virus vaccine
    RS virus

Phase 2

  • DS-3201 (JP)
    EZH1/2 inhibitor
    ATL/L
  • DS-3201 (JP/US/EU/Asia)
    EZH1/2 inhibitor
    PTCL
  • DS-1001 (JP)
    Mutant IDH1 inhibitor
    Glioma
  • DS-5141 (JP)
    ENA oligonucleotide DMD

Phase 3

  • Quizartinib (JP/US/EU/Asia)
    FLT3 inhibitor
    1L AML
  • Pexidartinib (JP/Asia)
    CSF-1/KIT/FLT3 inhibitor
    Tenosynovial giant cell tumor
  • Esaxerenone (JP)
    MR blocker
    Diabetic nephropathy
  • VN-0102/JVC-001 (JP)
    Measles mumps rubella
    combined vaccine

Submitted

  • Mirogabalin (JP)
    α2δ Ligands
    Central neuropathic pain
  • Edoxaban (JP)
    FXa inhibitor
    AF in the very elderly
  • Prasugrel (JP)
    ADP receptor inhibitor
    Ischemic stroke
  • VN-0107/MEDI3250 (JP)
    Live attenuated influenza vaccine nasal spray